☆ 4.5 Letter

Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two-year evaluation

PEDIATRIC ALLERGY AND IMMUNOLOGY (2023)

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL

Francesco Menzella et al.

Summary: This review examines the clinical efficacy of omalizumab in patients with severe allergic asthma with IgE levels exceeding the current dosing range. The results of the reviewed studies involving more than 3000 patients demonstrate that omalizumab significantly reduces exacerbations, improves asthma control and lung function, and enhances quality of life in these patients. Omalizumab is well-tolerated and has demonstrated efficacy and safety in other comorbidities of asthma as well. A detailed assessment and a proposed management algorithm for treating severe allergic asthma patients with IgE levels >1500 IU/mL are provided.

WORLD ALLERGY ORGANIZATION JOURNAL (2023)

添加到收藏夹

Review Allergy

Omalizumab as monotherapy for food allergy

Stefania Arasi et al.

Summary: Recent studies show that Omalizumab may be safe and effective in providing desensitization to one or several foods without requiring allergen exposure. Future advancements will guide the adoption of new food allergy treatments and allow the development of personalized treatment options.

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy